Showing 641-650 of 4344 results for "".
Systemic Treatment for Skin Cancers
https://practicaldermatology.com/topics/skin-cancer-photoprotection/systemic-treatment-for-skin-cancers/19662/Anisha B. Patel, MD discusses the latest advances in systemic treatment for melanoma with host Joshua Zeichner, MD. She reviews how treatments work, the most common cutaneous reactions patients experience, and the dermatologist's role in managing those reactions and reassuring patients that these reAnalyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuJournal Club: Biologics for Young Children
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databasePros and Cons of DTC Advertising
https://practicaldermatology.com/topics/practice-management/pros-and-cons-of-dtc-advertising/18569/Hilary Baldwin, MD and James Q. Del Rosso, DO sit down with Derm Insider Host Neal Bhatia, MD to weigh the pros and cons of direct-to-consumer advertising on patients. They agree that if done well and with a primary focus on disease state rather than a specific drug, these ads can encourage patientsDermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeBest practices to create demographic-targeted content
https://practicaldermatology.com/topics/practice-management/best-practices-to-create-demographic-targeted-content/18241/Invest in quality-oriented content development practices that can steer a digital marketing campaign towards better outcomes. This includes content distributed through various mediums. High-quality content with which people can identify and content with a human touch is critical for any digital markDermWireTV: Cassiopea NDA; Drew Barrymore and Paula Abdul Make Endorsements
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cassiopea-nda-drew-barrymore-and-paula-abdul-make-endorsements/19654/BTL’s new Emtone device targets cellulite via simultaneous thermal monopolar radiofrequency and mechanical targeted pressure energy to increase production of collagen and elastin. Drew Barrymore is brand ambassador for Emsculpt. Cassiopea has submitted a New Drug Application to the FDA seeking markeThe Dermatology & Aesthetics Markets: Retained Value In A New Normal
https://practicaldermatology.com/topics/practice-management/the-dermatology-aesthetics-markets-retained-value-in-a-new-normal/23583/Understanding new trends helps strengthen the dermatology and aesthetics markets, as well as shape practice decisions for the future.The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.